Cellular Mechanisms of GLP-1 Agonists: Treating Diabetes & Obesity Introduction Synthetic Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RAs) have revolutionized the treatment of type 2 diabetes and obesity
This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access 265,23 per year only 22,10 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
Long-acting amylin analogues for the management of obesity
The Precision Peptide Genetic Test may help provide context about your GLP1R and GIPR gene variants, which influence how effectively your body responds to GLP-1 therapy
Stay aware of how you feel, maintain adequate nutrition, and communicate openly with your healthcare providers
This article explores the current availability of GLP-1 medications in Canada, the legal and regulatory hurdles for U.S
